DoW Breast Cancer, Transformative Breast Cancer Consortium Award

The fiscal year 2026 Breast Cancer Research Program (BCRP) Transformative Breast Cancer Consortium Award supports collaborations and ideas that will transform the lives of individuals with, and/or at risk for, breast cancer. Applications must propose a synergistic, highly integrated, multidisciplinary and multi-institutional consortium of leading scientists, clinicians and breast cancer consumer advocates that will address a major problem in a way that a single investigator or group could not accomplish. The consortium’s collaborative efforts must make a transformative impact in breast cancer. Key features of this opportunity include: • Up to five Principal Investigators (PIs) are allowed, including the Consortium Director and three or four Project Team PIs. • Applications must include at least one breast cancer consumer advocate per project team. • Only the Consortium Director will submit a pre-application, but all PIs will need to submit at the full application stage. • The opportunity is open to unrestricted entities, subject to any clarification in the text field entitled "Additional Information on Eligibility".